Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable from Mon Nov 11 17:30 until Tue Nov 12 09:00 CET. Apologies for the inconvenience.

Cellosaurus TOV-21G (CVCL_3613)

[Text version]
Cell line name TOV-21G
Synonyms TOV-21g; TOV21G; TOV21
Accession CVCL_3613
Resource Identification Initiative To cite this cell line use: TOV-21G (RRID:CVCL_3613)
Comments Group: Patented cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: OCCP ovarian cancer cell line panel.
Part of: PTEN genetic alteration cell panel (ATCC TCP-1030).
Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11370.
Population: Caucasian.
Doubling time: 1.5 days (PubMed=10949993); 27 hours (PubMed=25984343); 30.62 hours (JWGray panel).
Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
Sequence variations
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Heterozygous (PubMed=22705003; PubMed=24224046; PubMed=25230021; PubMed=28273451; Cosmic-CLP=1240222; DepMap=ACH-000885).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Tyr (c.3139C>T); ClinVar=VCV000039705; Zygosity=Heterozygous (PubMed=22705003; PubMed=24224046; PubMed=25230021; PubMed=28273451; Cosmic-CLP=1240222; DepMap=ACH-000885).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (PubMed=25230021; Cosmic-CLP=1240222; DepMap=ACH-000885).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*11:01,26:01
HLA-BB*40:02,46:01
HLA-CC*02:02,04:01

Source: PubMed=26589293
Class I
HLA-AA*11:01,26:01
HLA-BB*40:02,40:02
HLA-CC*02:02,04:01
Class II
HLA-DQDQA1*04:01,04:01
DQB1*05:01,06:01
HLA-DRDRB1*01:01,11:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American1.11
East Asian, North0.06
East Asian, South0
South Asian1.64
European, North59.77
European, South37.42
Disease Ovarian clear cell adenocarcinoma (NCIt: C40078)
Clear cell adenocarcinoma of the ovary (ORDO: Orphanet_398971)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 62Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-3577; Cosmic-CLP=1240222; Direct_author_submission; PubMed=22710073; PubMed=25230021; PubMed=25877200; PubMed=30485824

Markers:
AmelogeninX
CSF1PO13,15
D2S133817
D3S135814,16
D5S81812,13
D7S82012
D8S117913,16
D13S31711,12
D16S53910,12
D18S5112 (PubMed=25230021; PubMed=25877200)
12,16 (PubMed=22710073)
D19S43314,16.2
D21S1128,34.2
FGA20,23
Penta D9
Penta E17,18 (PubMed=25877200)
17,19 (PubMed=25230021)
TH017,9.3
TPOX8,11
vWA17 (ATCC=CRL-3577; Cosmic-CLP=1240222; PubMed=22710073; PubMed=25230021; PubMed=25877200; PubMed=30485824)
17,18 (Direct_author_submission)

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
Publications

Patent=US5710038
Mes-Masson A.-M., Provencher D.M.
Primary cultures of normal and tumoral human ovarian epithelium.
Patent number US5710038, 20-Jan-1998

PubMed=10949993; DOI=10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2
Provencher D.M., Lounis H., Champoux L., Tetrault M., Manderson E.N., Wang J.-C., Eydoux P., Savoie R., Tonin P.N., Mes-Masson A.-M.
Characterization of four novel epithelial ovarian cancer cell lines.
In Vitro Cell. Dev. Biol. Anim. 36:357-361(2000)

PubMed=11641787; DOI=10.1038/sj.onc.1204804
Tonin P.N., Hudson T.J., Rodier F., Bossolasco M., Lee P.D., Novak J., Manderson E.N., Provencher D.M., Mes-Masson A.-M.
Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.
Oncogene 20:6617-6626(2001)

PubMed=19058220; DOI=10.1002/ijc.24058
Dafou D., Ramus S.J., Choi K., Grun B., Trott D.A., Newbold R.F., Jacobs I.J., Jones C., Gayther S.A.
Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells.
Int. J. Cancer 124:1037-1044(2009)

PubMed=20081105; DOI=10.1210/me.2009-0295; PMCID=PMC2817607
Nagaraja A.K., Creighton C.J., Yu Z.-F., Zhu H.-F., Gunaratne P.H., Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M., Anderson M.L., Matzuk M.M.
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.
Mol. Endocrinol. 24:447-463(2010)

PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445
Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
Oncol. Rep. 23:1021-1026(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011
Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M., Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M., Miyazaki K.
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Hum. Pathol. 43:2197-2206(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126.1-2126.10(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=24224046; DOI=10.1371/journal.pone.0080229; PMCID=PMC3817115
Zanaruddin S.N.S., Yee P.-S., Hor S.Y., Kong Y.H., Ghani W.M.N.W.A., Mustafa W.M.W., Zain R.B., Prime S.S., Rahman Z.A.A., Cheong S.-C.
Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
PLoS ONE 8:E80229-E80229(2013)

PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26388441; DOI=10.1016/j.cell.2015.08.056; PMCID=PMC4644236
Creixell P., Schoof E.M., Simpson C.D., Longden J., Miller C.J., Lou H.J., Perryman L., Cox T.R., Zivanovic N., Palmeri A., Wesolowska-Andersen A., Helmer-Citterich M., Ferkinghoff-Borg J., Itamochi H., Bodenmiller B., Erler J.T., Turk B.E., Linding R.
Kinome-wide decoding of network-attacking mutations rewiring cancer signaling.
Cell 163:202-217(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) ATCC; CRL-3577
ATCC; CRL-11730 - Discontinued
BCRC; 60407
BCRJ; 0236 - Discontinued
Cell line databases/resources CLO; CLO_0009385
cancercelllines; CVCL_3613
Cell_Model_Passport; SIDM01169
Cosmic-CLP; 1240222
DepMap; ACH-000885
LINCS_LDP; LCL-1530
Anatomy/cell type resources BTO; BTO:0005183
Biological sample resources BioSample; SAMN02800401
BioSample; SAMN03471875
BioSample; SAMN10988233
CRISP screens repositories BioGRID_ORCS_Cell_line; 446
Chemistry resources ChEMBL-Cells; CHEMBL4630710
ChEMBL-Targets; CHEMBL4630716
GDSC; 1240222
PharmacoDB; TOV21G_1605_2019
PubChem_Cell_line; CVCL_3613
Encyclopedic resources Wikidata; Q54972808
Experimental variables resources EFO; EFO_0022427
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM289385
GEO; GSM289386
GEO; GSM289416
GEO; GSM289417
GEO; GSM313692
GEO; GSM416684
GEO; GSM659408
GEO; GSM784567
GEO; GSM851945
GEO; GSM887711
GEO; GSM888804
GEO; GSM1176285
GEO; GSM1291153
GEO; GSM1374965
GEO; GSM1670547
GEO; GSM2475008
Polymorphism and mutation databases Cosmic; 1066220
Cosmic; 1102820
Cosmic; 1139221
Cosmic; 1223320
Cosmic; 1305319
Cosmic; 1312195
Cosmic; 1328069
Cosmic; 1434896
Cosmic; 1449932
Cosmic; 1707558
Cosmic; 1708383
Cosmic; 2074249
IARC_TP53; 21094
LiGeA; CCLE_476
Progenetix; CVCL_3613
Proteomic databases PRIDE; PXD000901
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number42